Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556164 | 0.79 | CTSK (0.40) | SSTR4SSTR1 | |
| SCHEMBL3355844 | 0.78 | HTR4 (0.41) | — | |
| SCHEMBL3355851 | 0.78 | HTR4 (0.41) | — | |
| SCHEMBL3353554 | 0.78 | HTR4 (0.41) | — | |
| SCHEMBL3383116 | 0.78 | HTR4 (0.41) | — | |
| SCHEMBL3353548 | 0.78 | HTR4 (0.41) | — | |
| SCHEMBL1920984 | 0.77 | MC4R (0.44) | SLC18A3KDM1AKMT2AMC4RPKM | |
| SCHEMBL28781924 | 0.76 | CTSK (0.48) | ALDH1A1KMT2A | |
| SCHEMBL1979937 | 0.76 | JAK1 (0.52) | KMT2A | |
| SCHEMBL3355594 | 0.76 | SSTR4 (0.38) | GSK3BDYRK1ASSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB | 2012-10-25 | — | — | US | disclosed |
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2121702-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | GSK3B 2760/4885DYRK1A 1166/4885SLC18A3 4283/4885 |
| US-20120270864-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | GSK3B 2760/4885DYRK1A 1166/4885SLC18A3 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.